BR0311732A - Proteìna de parceiro de fusão, sequência de ácido nucleico, vetor de expressão, hospedeiro, composição imunogênica, processo para a preparação de uma composição imunogênica, processo para produzir uma proteìna de fusão, uso de uma proteìna ou de uma sequência de dna, e, método para tratar um paciente que sofre de câncer - Google Patents
Proteìna de parceiro de fusão, sequência de ácido nucleico, vetor de expressão, hospedeiro, composição imunogênica, processo para a preparação de uma composição imunogênica, processo para produzir uma proteìna de fusão, uso de uma proteìna ou de uma sequência de dna, e, método para tratar um paciente que sofre de câncerInfo
- Publication number
- BR0311732A BR0311732A BR0311732-4A BR0311732A BR0311732A BR 0311732 A BR0311732 A BR 0311732A BR 0311732 A BR0311732 A BR 0311732A BR 0311732 A BR0311732 A BR 0311732A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- immunogenic composition
- fusion
- host
- nucleic acid
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 7
- 230000002163 immunogen Effects 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 101150016835 CPL1 gene Proteins 0.000 abstract 2
- 101100468774 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RIM13 gene Proteins 0.000 abstract 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract 2
- 229960001231 choline Drugs 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"PROTEìNA DE PARCEIRO DE FUSãO, SEQUêNCIA DE áCIDO NUCLEICO, VETOR DE EXPRESSãO, HOSPEDEIRO, COMPOSIçãO IMUNOGêNICA, PROCESSO PARA A PREPARAçãO DE UMA COMPOSIçãO IMUNOGêNICA, PROCESSO PARA PRODUZIR UMA PROTEìNA DE FUSãO, USO DE UMA PROTEìNA OU DE UMA SEQuêNCIA DE DNA, E, MéTODO PARA TRATAR UM PACIENTE QUE SOFRE DE CâNCER". A presente invenção refere-se a parceiros de fusão que atuam como parceiros de fusão imunológicos, como acentuadores de expressão e, de preferência, a parceiros de fusão apresentando ambas as funções. Em particular, os parceiros de fusão contêm um assim-chamado domínio de ligação de colina, por exemplo fusões compreendendo LytA de Streptococcus pneumoniae, ou o fago pneumocócico CP1 lisosima (CPL1) em que o domínio de ligação de colina é modificado de forma a incluir um epitopo de T-auxiliar heterólogo, e são fundidos a antígenos, particularmente antígenos fracamente imunogênicos, como auto-antígenos, p. ex. antígenos específicos para tumor ou específicos para tecido. A invenção refere-se também a proteínas de fusão contendo os mesmos, a sua fabricação, a seu uso em vacinas e composições imunogênicas e a seu uso em medicamentos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0213365.0A GB0213365D0 (en) | 2002-06-11 | 2002-06-11 | Novel compounds |
| GB0300914A GB0300914D0 (en) | 2003-01-15 | 2003-01-15 | Vaccines |
| PCT/EP2003/006096 WO2003104272A1 (en) | 2002-06-11 | 2003-06-06 | Immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311732A true BR0311732A (pt) | 2005-03-01 |
Family
ID=29738082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311732-4A BR0311732A (pt) | 2002-06-11 | 2003-06-06 | Proteìna de parceiro de fusão, sequência de ácido nucleico, vetor de expressão, hospedeiro, composição imunogênica, processo para a preparação de uma composição imunogênica, processo para produzir uma proteìna de fusão, uso de uma proteìna ou de uma sequência de dna, e, método para tratar um paciente que sofre de câncer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20060147477A1 (pt) |
| EP (1) | EP1511768B1 (pt) |
| JP (1) | JP2006512047A (pt) |
| KR (1) | KR20050010040A (pt) |
| CN (1) | CN100360558C (pt) |
| AR (1) | AR040178A1 (pt) |
| AT (1) | ATE359295T1 (pt) |
| AU (1) | AU2003246411A1 (pt) |
| BR (1) | BR0311732A (pt) |
| CA (1) | CA2487831A1 (pt) |
| CO (1) | CO5631450A2 (pt) |
| DE (1) | DE60313163T2 (pt) |
| DK (1) | DK1511768T3 (pt) |
| ES (1) | ES2285174T3 (pt) |
| HK (1) | HK1074846A1 (pt) |
| IL (1) | IL165372A0 (pt) |
| IS (1) | IS7547A (pt) |
| MX (1) | MXPA04012443A (pt) |
| MY (1) | MY139557A (pt) |
| NO (1) | NO20045148L (pt) |
| NZ (1) | NZ537125A (pt) |
| PE (1) | PE20040554A1 (pt) |
| PL (1) | PL374534A1 (pt) |
| PT (1) | PT1511768E (pt) |
| RU (1) | RU2004135541A (pt) |
| TW (1) | TW200400970A (pt) |
| UY (1) | UY27840A1 (pt) |
| WO (1) | WO2003104272A1 (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| AU2005249212B2 (en) * | 2004-05-28 | 2010-05-20 | Glaxosmithkline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2595778A1 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
| JP2009528984A (ja) * | 2006-01-27 | 2009-08-13 | ザ・ユニバーシティ・オブ・ミシシッピ・メディカル・センター | ドキソルビシンを含む医薬の熱標的化送達 |
| AR061136A1 (es) | 2006-06-02 | 2008-08-06 | Glaxosmithkline Biolog Sa | Procedimiento |
| NZ577405A (en) * | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| ES2321788B1 (es) * | 2007-01-29 | 2010-03-11 | Universidad Miguel Hernandez | Dominios proteicos de afinidad a colina para mejorar la expresion, inmovilizacion y purificacion de polipetidos. |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| WO2009046739A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
| WO2009114202A2 (en) * | 2008-03-14 | 2009-09-17 | The United States Of America As Represented By The Secretary Of The Navy | Vaccine and immunization method using plasmodium antigen 2 |
| WO2010036293A1 (en) * | 2008-09-24 | 2010-04-01 | The Johns Hokins University | Malaria vaccine |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| DK2396032T3 (en) | 2009-02-10 | 2016-12-19 | Seqirus Uk Ltd | Influenza vaccines with reduced amounts of squalene |
| US20110229514A1 (en) * | 2009-03-16 | 2011-09-22 | Denise Doolan | Vaccine and immunization method using plasmodium antigen 2 |
| CA2756533A1 (en) | 2009-03-24 | 2010-09-30 | Novartis Ag | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| TR201802380T4 (tr) | 2009-06-10 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Benzonaftiridin içeren aşılar. |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| JP5814933B2 (ja) | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | 免疫増強化合物の均質な懸濁物およびその使用 |
| DK2528621T3 (da) * | 2010-01-27 | 2017-01-02 | Glaxosmithkline Biologicals Sa | Modificerede tuberkuloseantigener |
| EP2549990A1 (en) | 2010-03-23 | 2013-01-30 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| DK2598165T3 (en) | 2010-07-26 | 2017-10-16 | Qu Biologics Inc | IMMUNOGENIC ANTI-INFLAMMATORY COMPOSITIONS |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| MX352892B (es) * | 2011-08-17 | 2017-12-13 | Globeimmune Inc | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| CN105188747A (zh) | 2013-02-01 | 2015-12-23 | 葛兰素史密斯克莱生物公司 | 包含toll样受体激动剂的免疫组合物的皮内递送 |
| RU2598265C2 (ru) * | 2013-07-26 | 2016-09-20 | Амир Закиевич Максютов | Полиэпитопные иммуногенные полипептиды и способы их применения |
| CN106456740B (zh) | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
| CN108164586B (zh) * | 2018-01-22 | 2021-03-26 | 西南医科大学 | 合成多肽及其应用 |
| KR20200123436A (ko) | 2018-02-12 | 2020-10-29 | 이니뮨 코퍼레이션 | 톨-유사 수용체 리간드 |
| FR3100819B1 (fr) * | 2019-09-18 | 2024-04-19 | Centre Nat Rech Scient | Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques |
| CN110922455B (zh) * | 2019-12-28 | 2023-01-13 | 重庆艾力彼生物科技有限公司 | 铜绿假单胞菌疫苗重组蛋白rePilA-FliC及制备方法和应用 |
| IL302449A (en) | 2020-11-04 | 2023-06-01 | Eligo Bioscience | CUTIBACTERIUM ACNES PHAGES RECOMBINANT, the production method and their uses |
| CN113278078B (zh) * | 2021-05-25 | 2023-03-21 | 西南医科大学 | 多肽序列及其应用 |
| CN116875520B (zh) * | 2023-07-12 | 2024-06-14 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
| CN117003890B (zh) * | 2023-08-09 | 2024-06-04 | 成都新诺明生物科技有限公司 | 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395278B1 (en) * | 1997-02-25 | 2002-05-28 | Corixa Corporation | Prostate specific fusion protein compositions |
| TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| US6090388A (en) * | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| EP1870466A3 (en) * | 1998-07-14 | 2008-03-19 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| AU2027400A (en) * | 1998-11-19 | 2000-06-05 | St. Jude Children's Research Hospital | Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof |
| WO2001034802A2 (en) * | 1999-11-12 | 2001-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| BR0107643A (pt) * | 2000-01-14 | 2003-06-10 | Corixa Corp | Composições e processos para a terapia e diagnóstico de c ncer de próstata |
| AU2001249549A1 (en) * | 2000-03-27 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
-
2003
- 2003-06-06 DE DE60313163T patent/DE60313163T2/de not_active Expired - Fee Related
- 2003-06-06 PL PL03374534A patent/PL374534A1/xx not_active Application Discontinuation
- 2003-06-06 DK DK03757056T patent/DK1511768T3/da active
- 2003-06-06 CN CNB038194872A patent/CN100360558C/zh not_active Expired - Fee Related
- 2003-06-06 ES ES03757056T patent/ES2285174T3/es not_active Expired - Lifetime
- 2003-06-06 AT AT03757056T patent/ATE359295T1/de not_active IP Right Cessation
- 2003-06-06 MX MXPA04012443A patent/MXPA04012443A/es not_active Application Discontinuation
- 2003-06-06 AU AU2003246411A patent/AU2003246411A1/en not_active Abandoned
- 2003-06-06 JP JP2004511340A patent/JP2006512047A/ja active Pending
- 2003-06-06 PT PT03757056T patent/PT1511768E/pt unknown
- 2003-06-06 EP EP03757056A patent/EP1511768B1/en not_active Expired - Lifetime
- 2003-06-06 KR KR10-2004-7020138A patent/KR20050010040A/ko not_active Application Discontinuation
- 2003-06-06 IL IL16537203A patent/IL165372A0/xx unknown
- 2003-06-06 RU RU2004135541/13A patent/RU2004135541A/ru not_active Application Discontinuation
- 2003-06-06 CA CA002487831A patent/CA2487831A1/en not_active Abandoned
- 2003-06-06 BR BR0311732-4A patent/BR0311732A/pt not_active IP Right Cessation
- 2003-06-06 US US10/517,420 patent/US20060147477A1/en not_active Abandoned
- 2003-06-06 NZ NZ537125A patent/NZ537125A/en unknown
- 2003-06-06 WO PCT/EP2003/006096 patent/WO2003104272A1/en active IP Right Grant
- 2003-06-09 UY UY27840A patent/UY27840A1/es unknown
- 2003-06-09 TW TW092115540A patent/TW200400970A/zh unknown
- 2003-06-09 PE PE2003000573A patent/PE20040554A1/es not_active Application Discontinuation
- 2003-06-09 AR ARP030102046A patent/AR040178A1/es not_active Application Discontinuation
- 2003-06-09 MY MYPI20032146A patent/MY139557A/en unknown
-
2004
- 2004-11-23 IS IS7547A patent/IS7547A/is unknown
- 2004-11-25 NO NO20045148A patent/NO20045148L/no not_active Application Discontinuation
- 2004-12-06 CO CO04122511A patent/CO5631450A2/es not_active Application Discontinuation
-
2005
- 2005-08-17 HK HK05107152A patent/HK1074846A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60313163D1 (de) | 2007-05-24 |
| HK1074846A1 (en) | 2005-11-25 |
| CO5631450A2 (es) | 2006-04-28 |
| CN1675237A (zh) | 2005-09-28 |
| AU2003246411A1 (en) | 2003-12-22 |
| WO2003104272A1 (en) | 2003-12-18 |
| ATE359295T1 (de) | 2007-05-15 |
| PE20040554A1 (es) | 2004-09-30 |
| AR040178A1 (es) | 2005-03-16 |
| MY139557A (en) | 2009-10-30 |
| RU2004135541A (ru) | 2005-10-10 |
| ES2285174T3 (es) | 2007-11-16 |
| PL374534A1 (en) | 2005-10-31 |
| CA2487831A1 (en) | 2003-12-18 |
| NO20045148L (no) | 2005-03-01 |
| EP1511768B1 (en) | 2007-04-11 |
| EP1511768A1 (en) | 2005-03-09 |
| DK1511768T3 (da) | 2007-08-20 |
| UY27840A1 (es) | 2003-12-31 |
| US20060147477A1 (en) | 2006-07-06 |
| KR20050010040A (ko) | 2005-01-26 |
| CN100360558C (zh) | 2008-01-09 |
| PT1511768E (pt) | 2007-07-16 |
| TW200400970A (en) | 2004-01-16 |
| IS7547A (is) | 2004-11-23 |
| IL165372A0 (en) | 2006-01-15 |
| DE60313163T2 (de) | 2008-01-03 |
| MXPA04012443A (es) | 2005-04-19 |
| JP2006512047A (ja) | 2006-04-13 |
| NZ537125A (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0311732A (pt) | Proteìna de parceiro de fusão, sequência de ácido nucleico, vetor de expressão, hospedeiro, composição imunogênica, processo para a preparação de uma composição imunogênica, processo para produzir uma proteìna de fusão, uso de uma proteìna ou de uma sequência de dna, e, método para tratar um paciente que sofre de câncer | |
| Silva et al. | Effects of hydrostatic pressure on a membrane-enveloped virus: high immunogenicity of the pressure-inactivated virus | |
| NO20013701L (no) | HER-2/neu-fusjonsproteiner | |
| BR9907691A (pt) | Derivados de antìgeno associado a tumor da famìlia mage, e sequências de ácido nucléico codificando os mesmos, usados para a preparação de proteìnas de fusão e de composições para vacinação | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| BR0214137A (pt) | Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos | |
| WO2002012341A3 (en) | Her-2/neu fusion proteins | |
| BR0015137A (pt) | Peptìdeos antigênicos de neisseria | |
| BRPI0511118A (pt) | polipeptìdeos de haemophilus influenzae não transcritos | |
| ID23855A (id) | Protein pengikat osteoprotegerin dan reseptor | |
| BRPI0418766A (pt) | anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1 | |
| NO994983L (no) | Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse | |
| DK0853487T3 (da) | Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus | |
| PT96097A (pt) | Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados | |
| BR0213941A (pt) | Arranjos de antìgeno para o tratamento de doença óssea | |
| WO2000025722A3 (en) | ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS | |
| BR0311211A (pt) | Molécula de ácido nucleico codificando um antìgeno de muc-1, plasmìdeo, proteìna, composição farmacêutica, usos de uma molécula de ácido nucleico e de uma proteìna, e, método para tratar ou prevenir tumores ou metástases | |
| NO20053363L (no) | Malrettede enkle epitoper. | |
| DE60121317T2 (de) | Materialen und verfahren mit bezug auf immunantworten gegen fusionsproteine | |
| BR0015597A (pt) | Uso de anticorpos como vacinas | |
| JPS6168427A (ja) | 腫瘍治療剤およびその製法 | |
| Dubreuil et al. | Interrelationships among the plasma membrane, the membrane skeleton and surface form in a unicellular flagellate | |
| BR9709993A (pt) | Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica | |
| CN115003690B (zh) | 重组生长分化因子11(gdf11) | |
| Schwarzbauer et al. | Evidence that E. coli ribosomal protein S13 has two separable functional domains involved in 16S RNA recognition and protein S19 binding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6 DA RPI 2116 DE 26/07/2011. |